Clinical Trial: Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor - A Double-blinded, Placebo-controlled, Randomized, Multicenter, Development Phase II Study
Brief Summary: Ticagrelor treatment is associated with increased rates of dyspnea, where previous studies have implied a possible role of adenosine. The purpose of this study is to determine if the caffeine-antagonist is effective in reducing dyspnea related to ticagrelor.
Detailed Summary:
Sponsor: Uppsala University
Current Primary Outcome: Visual analog scale area under the curve (VAS-AUC) for dyspnea [ Time Frame: 7-10 days ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- High on-treatment platelet reactivity by VerifyNow [ Time Frame: 7-10 days ]
- Change in dyspnea by 7-point Likert scale [ Time Frame: 7-10 days ]
Original Secondary Outcome: Same as current
Information By: Uppsala University
Dates:
Date Received: December 4, 2014
Date Started: December 2014
Date Completion:
Last Updated: February 5, 2016
Last Verified: February 2016
